Endothelium in Hypertension: Nitric Oxide

Hypertension

Volumn , Issue , 2005, Pages 146-158

  Spieker, Lukas E ^a   Lüscher, Thomas F ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84884852876     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-7216-0258-5.50106-X     Document Type: Chapter

References (204)

1. Lüscher TF, Vanhoutte PM The Endothelium: Modulator of Cardiovascular Function 1990, CRC Press, Boca Raton.
2. Furchgott RF, Zawadzki JV The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980, 288:373-376.
3. Rubanyi GM, Romero JC, Vanhoutte PM Flow-induced release of endothelium-derived relaxing factor. Am J Physiol 1986, 250:H1145-H1149.
4. Anderson EA, Mark AL Flow-mediated and reflex changes in large peripheral artery tone in humans. Circulation 1989, 79:93-100.
5. Palmer RM, Ferrige AG, Moncada S Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987, 327:524-526.
6. Stamler JS, Singel DJ, Loscalzo J Biochemistry of nitric oxide and its redox-activated forms. Science 1992, 258:1898-1902.
7. Palmer RM, Ashton DS, Moncada S Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature 1988, 333:664-666.
8. Palmer RMJ, Rees DD, Ashton DS, Moncada S L-arginine is the physiological precursor for the formation of nitric oxide in endothelium-dependent relaxation. Biochem Biophys Res Commun 1988, 153:1251-1256.
9. Palmer RM, Bridge L, Foxwell NA, et al. The role of nitric oxide in endothelial cell damage and its inhibition by glucocorticoids. Br J Pharmacol 1992, 105:11-12.
10. Lüscher TF, Vanhoutte PM Endothelium-dependent contractions to acetylcholine in the aorta of the spontaneously hypertensive rat. Hypertension 1986, 8:344-348.
11. Lüscher TF, Romero JC, Vanhoutte PM Bioassay of endothelium-derived substances in the aorta of normotensive and spontaneously hypertensive rats. J Hypertension 1986, 4(Suppl 6):81.
12. Dohi Y, Thiel MA, Bühler FR, Lüscher TF Activation of endothelial L-arginine pathway in resistance arteries. Effect of age and hypertension. Hypertension 1990, 16:170-179.
13. Diederich D, Yang ZH, Bühler FR, et al. Impaired endothelium-dependent relaxations in hypertensive resistance arteries involve cyclooxygenase pathway. Am J Physiol 1990, 258:H445-H451.
14. Nava E, Farre AL, Moreno C, et al. Alterations to the nitric oxide pathway in the spontaneously hypertensive rat. J Hypertens 1998, 16:609-615.
15. Kelm M, Feelisch M, Krebber T, et al. The role of nitric oxide in the regulation of coronary vascular resistance in arterial hypertension: Comparison of normotensive and spontaneously hypertensive rats. J Cardiovasc Pharmacol 1992, 20:S183-S186.
16. Nava E, Noll G, Lüscher TF Increased activity of constitutive nitric oxide synthase in cardiac endothelium in spontaneous hypertension. Circulation 1995, 91:2310-2313.
17. Grunfeld S, Hamilton CA, Mesaros S, et al. Role of superoxide in the depressed nitric oxide production by the endothelium of genetically hypertensive rats. Hypertension 1995, 26:854-857.
18. McIntyre M, Hamilton CA, Rees DD, et al. Sex differences in the abundance of endothelial nitric oxide in a model of genetic hypertension. Hypertension 1997, 30:1517-1524.
19. Tschudi MR, Mesaros S, Luscher TF, et al. Direct in situ measurement of nitric oxide in mesenteric resistance arteries. Increased decomposition by superoxide in hypertension. Hypertension 1996, 27:32-35.
20. Lüscher TF, Raij L, Vanhoutte PM Endothelium-dependent vascular responses in normotensive and hypertensive Dahl rats. Hypertension 1987, 9:157-163.
21. Lee J, Choi KC, Yeum CH, et al. Impairment of endothelium-dependent vasorelaxation in chronic two-kidney, one clip hypertensive rats. Nephrol Dial Transplant 1995, 10:619-623.
22. Hayakawa H, Hirata Y, Suzuki E, et al. Mechanisms for altered endothelium-dependent vasorelaxation in isolated kidneys from experimental hypertensive rats. Am J Physiol 1993, 264:H1535-H1541.
23. Hirata Y, Hayakawa H, Suzuki E, et al. Direct measurements of endothelium-derived nitric oxide release by stimulation of endothelin receptors in rat kidney and its alteration in salt-induced hypertension. Circulation 1995, 91:1229-1235.
24. Dohi Y, Criscione L, Luscher TF Renovascular hypertension impairs formation of endothelium-derived relaxing factors and sensitivity to endothelin-1 in resistance arteries. Br J Pharmacol 1991, 104:349-354.
25. Kakoki M, Hirata Y, Hayakawa H, et al. Effects of hypertension, diabetes mellitus, and hypercholesterolemia on endothelin type B receptor-mediated nitric oxide release from rat kidney. Circulation 1999, 99:1242-1248.
26. Ni Z, Oveisi F, Vaziri ND Nitric oxide synthase isotype expression in salt-sensitive and salt-resistant Dahl rats. Hypertension 1999, 34:552-557.
27. Chen PY, Sanders PW L-arginine abrogates salt-sensitive hypertension in Dahl/Rapp rats. J Clin Invest 1991, 88:1559-1567.
28. Chen PY, St.John PL, Kirk KA, et al. Hypertensive nephrosclerosis in the Dahl/Rapp rat. Initial sites of injury and effect of dietary L-arginine supplementation. Lab Invest 1993, 68:174-184.
29. Chen PY, Sanders PW Role of nitric oxide synthesis in salt-sensitive hypertension in Dahl/Rapp rats. Hypertension 1993, 22:812-818.
30. Hu L, Manning RD Role of nitric oxide in regulation of long-term pressure-natriuresis relationship in Dahl rats. Am J Physiol 1995, 268:H2375-H2383.
31. Matsuoka H, Itoh S, Kimoto M, et al. Asymmetrical dimethy-larginine, an endogenous nitric oxide synthase inhibitor, in experimental hypertension. Hypertension 1997, 29:242-247.
32. Deng AY, Rapp JP Locus for the inducible, but not a constitutive, nitric oxide synthase cosegregates with blood pressure in the Dahl salt-sensitive rat. J Clin Invest 1995, 95:2170-2177.
33. Ikeda Y, Saito K, Kim JI, et al. Nitric oxide synthase isoform activities in kidney of Dahl salt-sensitive rats. Hypertension 1995, 26:1030-1034.
34. Simchon S, Manger W, Blumberg G, et al. Impaired renal vasodilation and urinary cGMP excretion in Dahl salt-sensitive rats. Hypertension 1996, 27:653-657.
35. Rudd MA, Trolliet M, Hope S, et al. Salt-induced hypertension in Dahl salt-resistant and salt-sensitive rats with NOS II inhibition. Am J Physiol 1999, 277:H732-H739.
36. Linder L, Kiowski W, Bühler FR, et al. Indirect evidence for release of endothelium-derived relaxing factor in human forearm circulation in vivo: Blunted response in essential hypertension. Circulation 1990, 81:1762-1767.
37. Panza JA, Quyyumi AA, Brush JJ, et al. Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. N Engl J Med 1990, 323:22-27.
38. Hirooka Y, Imaizumi T, Masaki H, et al. Captopril improves impaired endothelium-dependent vasodilation in hypertensive patients. Hypertension 1992, 20:175-180.
39. Panza JA, Casino PR, Kilcoyne CM, et al. Role of endothelium-derived nitric oxide in the abnormal endothelium-dependent vascular relaxation of patients with essential hypertension. Circulation 1993, 87:1468-1474.
40. Panza JA, Quyyumi AA, Callahan TS, et al. Effect of antihypertensive treatment on endothelium-dependent vascular relaxation in patients with essential hypertension. J Am Coll Cardiol 1993, 21:1145-1151.
41. Panza JA, Casino PR, Badar DM, Quyyumi AA Effect of increased availability of endothelium-derived nitric oxide precursor on endothelium-dependent vascular relaxation in normal subjects and in patients with essential hypertension. Circulation 1993, 87:1475-1481.
42. Taddei S, Mattei P, Virdis A, et al. Effect of potassium on vasodilation to acetylcholine in essential hypertension. Hypertension 1994, 23:485-490.
43. Creager MA, Roddy MA Effect of captopril and enalapril on endothelial function in hypertensive patients. Hypertension 1994, 24:499-505.
44. Panza JA, Casino PR, Kilcoyne CM, et al. Impaired endothelium-dependent vasodilation in patients with essential hypertension: Evidence that the abnormality is not at the muscarinic receptor level. J Am Coll Cardiol 1994, 23:1610-1616.
45. Taddei S, Virdis A, Mattei P, et al. Aging and endothelial function in normotensive subjects and patients with essential hypertension. Circulation 1995, 91:1981-1987.
46. Taddei S, Virdis A, Mattei P, et al. Hypertension causes premature aging of endothelial function in humans. Hypertension 1997, 29:736-743.
47. Treasure CB, Klein JL, Vita JA, et al. Hypertension and left ventricular hypertrophy are associated with impaired endothelium-mediated relaxation in human coronary resistance vessels. Circulation 1993, 87:86-93.
48. Egashira K, Suzuki S, Hirooka Y, et al. Impaired endothelium-dependent vasodilation of large epicardial and resistance coronary arteries in patients with essential hypertension: Different responses to acetylcholine and substance P. Hypertension 1995, 25:201-206.
49. Anderson TJ, Uehata A, Gerhard MD, et al. Close relation of endothelial function in the human coronary and peripheral circulation. J Am Coll Cardiol 1995, 26:1235-1241.
50. Takase B, Uehata A, Akima T, et al. Endothelium-dependent flow-mediated vasodilation in coronary and brachial arteries in suspected coronary artery disease. Am J Cardiol 1998, 82:1535-1539, A7-A8.
51. Calver A, Collier J, Moncada S, Vallance P Effect of local intraarterial NG-monomethyl-L-arginine in patients with hypertension: The nitric oxide dilator mechanism appears abnormal. J Hypertens 1992, 10:1025-1031.
52. Forte P, Copland M, Smith LM, Milne E, Sutherland J, Benjamin N Basal nitric oxide synthesis in essential hypertension. Lancet 1997, 349:837-842.
53. Taddei S, Virdis A, Ghiadoni L, et al. Vasoconstriction to endogenous endothelin-1 is increased in the peripheral circulation of patients with essential hypertension. Circulation 1999, 100:1680-1683.
54. Taddei S, Virdis A, Mattei P, et al. Endothelium-dependent forearm vasodilation is reduced in normotensive subjects with familial history of hypertension. J Cardiovasc Pharmacol 1992, 20:S193-S195.
55. McAllister AS, Atkinson AB, Johnston GD, et al. Basal nitric oxide production is impaired in offspring of patients with essential hypertension. Clin Sci (Colch) 1999, 97:141-147.
56. Millgard J, Lind L Acute hypertension impairs endothelium-dependent vasodilation. Clin Sci (Colch) 1998, 94:601-607.
57. Rubanyi GM, Vanhoutte PM Superoxide anions and hyperoxia inactivate endothelium-derived relaxing factor. Am J Physiol 1986, 250:H822-H827.
58. Katusic ZS, Vanhoutte PM Superoxide anion is an endothelium-derived contracting factor. Am J Physiol 1989, 257:H33-H37.
59. Auch-Schwelk W, Katusic ZS, Vanhoutte PM Contractions to oxygen-derived free radicals are augmented in aorta of the spontaneously hypertensive rat. Hypertension 1989, 13:859-864.
60. Cosentino F, Sill JC, Katusic ZS Role of superoxide anions in the mediation of endothelium-dependent contractions. Hypertension 1994, 23:223-235.
61. Katusic ZS, Schugel J, Cosentino F, et al. Endothelium-dependent contractions to oxygen-derived free radicals in the canine basilar artery. Am J Physiol 1993, 264:H859-H864.
62. Turrens JF, Boveris A Generation of superoxide anion by the NADH dehydrogenase of bovine heart mitochondria. Biochem J 1980, 191:421-427.
63. Hishikawa K, Oemar BS, Yang Z, et al. Pulsatile stretch stimulates superoxide production and activates nuclear factor-kappa B in human coronary smooth muscle. Circ Res 1997, 81:797-803.
64. Kontos HA, Wei EP, Ellis EF, et al. Appearance of superoxide anion radical in cerebral extracellular space during increased prostaglandin synthesis in cats. Circ Res 1985, 57:142-151.
65. Cardillo C, Kilcoyne CM, Cannon RO, et al. Xanthine oxidase inhibition with oxypurinol improves endothelial vasodilator function in hypercholesterolemic but not in hypertensive patients. Hypertension 1997, 30:57-63.
66. Cosentino F, Patton S, d'Uscio LV, et al. Tetrahydrobiopterin alters superoxide and nitric oxide release in prehypertensive rats. J Clin Invest 1998, 101:1530-1537.
67. Stroes E, Hijmering M, van Zandvoort M, et al. Origin of superoxide production by endothelial nitric oxide synthase. FEBS Lett 1998, 438:161-164.
68. Kerr S, Brosnan MJ, McIntyre M, et al. Superoxide anion production is increased in a model of genetic hypertension: Role of the endothelium. Hypertension 1999, 33:1353-1358.
69. Jameson M, Dai FX, Luscher T, et al. Endothelium-derived contracting factors in resistance arteries of young spontaneously hypertensive rats before development of overt hypertension. Hypertension 1993, 21:280-288.
70. Fridovich I, Freeman B Antioxidant defenses in the lung. Annu Rev Physiol 1986, 48:693-702.
71. Thomson L, Trujillo M, Telleri R, et al. Kinetics of cytochrome c2+ oxidation by peroxynitrite: Implications for superoxide measurements in nitric oxide-producing biological systems. Arch Biochem Biophys 1995, 319:491-497.
72. Levanon D, Lieman-Hurwitz J, Dafni N, et al. Architecture and anatomy of the chromosomal locus in human chromosome 21 encoding the Cu/Zn superoxide dismutase. EMBO J 1985, 4:77-84.
73. De La Torre R, Casado A, Lopez-Fernandez E, et al. Overexpression of copper-zinc superoxide dismutase in trisomy 21. Experientia 1996, 52:871-873.
74. Morrison RA, McGrath A, Davidson G, et al. Low blood pressure in Down's syndrome: A link with Alzheimer's disease?. Hypertension 1996, 28:569-575.
75. Goldblatt H, Lynch J, Hanzal RF, et al. Studies on experimental hypertension, I: The production of persistent elevation of systolic blood pressure by means of renal ischemia. J Exp Med 1934, 59:347-379.
76. Fukui T, Ishizaka N, Rajagopalan S, et al. p22phox mRNA expression and NADPH oxidase activity are increased in aortas from hypertensive rats. Circ Res 1997, 80:45-51.
77. Rajagopalan S, Kurz S, Munzel T, et al. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. J Clin Invest 1996, 97:1916-1923.
78. Laursen JB, Rajagopalan S, Galis Z, et al. Role of superoxide in angiotensin II-induced but not catecholamine-induced hypertension. Circulation 1997, 95:588-593.
79. Zafari AM, Ushio-Fukai M, Akers M, et al. Role of NADH/NADPH oxidase-derived H2O2 in angiotensin II-induced vascular hypertrophy. Hypertension 1998, 32:488-495.
80. Dijkhorst-Oei LT, Stroes ES, Koomans HA, et al. Acute simultaneous stimulation of nitric oxide and oxygen radicals by angiotensin II in humans in vivo. J Cardiovasc Pharmacol 1999, 33:420-424.
81. Moreau P, d'Uscio LV, Shaw S, et al. Angiotensin II increases tissue endothelin and induces vascular hypertrophy: Reversal by ET(A)-receptor antagonist. Circulation 1997, 96:1593-1597.
82. Pohl U, Holtz J, Busse R, et al. Crucial role of endothelium in the vasodilator response to increased flow in vivo. Hypertension 1986, 8:37-44.
83. Koller A, Kaley G Prostaglandins mediate arteriolar dilation to increased blood flow velocity in skeletal muscle microcirculation. Circ Res 1990, 67:529-534.
84. Okahara K, Sun B, Kambayashi J Upregulation of prostacyclin synthesis-related gene expression by shear stress in vascular endothelial cells. Arterioscler Thromb Vasc Biol 1998, 18:1922-1926.
85. Moncada S, Gryglewski R, Bunting S, Vane JR An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature 1976, 263:663-665.
86. Joannides R, Haefeli WE, Linder L, et al. Nitric oxide is responsible for flow-dependent dilatation of human peripheral conduit arteries in vivo. Circulation 1995, 91:1314-1319.
87. Radomski MW, Palmer RM, Moncada S Comparative pharmacology of endothelium-derived relaxing factor, nitric oxide and prostacyclin in platelets. Br J Pharmacol 1987, 92:181-187.
88. Chenevard R, Hurlimann D, Bechir M, et al. Selective COX-2 inhibition improves endothelial function in coronary artery disease. Circulation 2003, 107:405-409.
89. Küng CF, Lüscher TF Different mechanisms of endothelial dysfunction with aging and hypertension in rat aorta. Hypertension 1995, 25:194-200.
90. Noll G, Lang MG, Tschudi MR, et al. Endothelial vasoconstrictor prostanoids modulate contractions to acetylcholine and ANG II in Ren-2 rats. Am J Physiol 1997, 272:H493-H500.
91. Yang ZH, von Segesser L, Bauer E, et al. Different activation of the endothelial L-arginine and cyclooxygenase pathway in the human internal mammary artery and saphenous vein. Circ Res 1991, 68:52-60.
92. Taddei S, Virdis A, Ghiadoni L, et al. Cyclooxygenase inhibition restores nitric oxide activity in essential hypertension. Hypertension 1997, 29:274-279.
93. Richard V, Tanner FC, Tschudi M, et al. Different activation of L-arginine pathway by bradykinin, serotonin, and clonidine in coronary arteries. Am J Physiol 1990, 259:H1433-H1439.
94. Vanhoutte PM Vascular physiology: The end of the quest? [news]. Nature 1987, 327:459-460.
95. Taylor SG, Weston AH Endothelium-derived hyperpolarizing factor: A new endogenous inhibitor from the vascular endothelium. Trends Pharmacol Sci 1988, 9:272-274.
96. Van de Voorde J, Vanheel B, Leusen I Endothelium-dependent relaxation and hyperpolarization in aorta from control and renal hypertensive rats. Circ Res 1992, 70:1-8.
97. Fujii K, Tominaga M, Ohmori S, et al. Decreased endothelium-dependent hyperpolarization to acetylcholine in smooth muscle of the mesenteric artery of spontaneously hypertensive rats. Circ Res 1992, 70:660-669.
98. Edwards G, Dora KA, Gardener MJ, Garland CJ, Weston AH K+ is an endothelium-derived hyperpolarizing factor in rat arteries. Nature 1998, 396:269-272.
99. Takase H, Moreau P, Kung CF, et al. Antihypertensive therapy prevents endothelial dysfunction in chronic nitric oxide deficiency. Effect of verapamil and trandolapril. Hypertension 1996, 27:25-31.
100. Taddei S, Ghiadoni L, Virdis A, et al. Vasodilation to bradykinin is mediated by an ouabain-sensitive pathway as a compensatory mechanism for impaired nitric oxide availability in essential hypertensive patients. Circulation 1999, 100:1400-1405.
101. Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988, 332:411-415.
102. Hickey KA, Rubanyi G, Paul RJ, et al. Characterization of a coronary vasoconstrictor produced by cultured endothelial cells. Am J Physiol 1985, 248:C550-C556.
103. Ikegawa R, Matsumura Y, Tsukahara Y, et al. Phosphoramidon, a metalloproteinase inhibitor, suppresses the secretion of endothelin-1 from cultured endothelial cells by inhibiting a big endothelin-1 converting enzyme. Biochem Biophys Res Commun 1990, 171:669-675.
104. Takahashi M, Matsushita Y, Iijima Y, et al. Purification and characterization of endothelin-converting enzyme from rat lung. J Biol Chem 1993, 268:21394-21398.
105. Ohnaka K, Takayanagi R, Nishikawa M, et al. Purification and characterization of a phosphoramidon-sensitive endothelin-converting enzyme in porcine aortic endothelium. J Biol Chem 1993, 268:26759-26766.
106. Shimada K, Takahashi M, Tanzawa K Cloning and functional expression of endothelin-converting enzyme from rat endothelial cells. J Biol Chem 1994, 269:18275-18278.
107. Rossi GP, Albertin G, Franchin E, et al. Expression of the endothelin-converting enzyme gene in human tissues. Biochem Biophys Res Commun 1995, 211:249-253.
108. Inoue A, Yanagisawa M, Takuwa Y, et al. The human preproen-dothelin-1 gene. Complete nucleotide sequence and regulation of expression. J Biol Chem 1989, 264:14954-14959.
109. Inoue A, Yanagisawa M, Kimura S, et al. The human endothelin family: Three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc Natl Acad Sci USA 1989, 86:2863-2867.
110. Fleminger G, Bousso-Mittler D, Bdolah A, et al. Immunological and structural characterization of sarafo-toxin/endothelin family of peptides. Biochem Biophys Res Commun 1989, 162:1317-1323.
111. Kloog Y, Bousso-Mittler D, Bdolah A, et al. Three apparent receptor subtypes for the endothelin/sarafotoxin family. FEBS Lett 1989, 253:199-202.
112. Kloog Y, Ambar I, Sokolovsky M, et al. Sarafotoxin, a novel vasoconstrictor peptide: Phosphoinositide hydrolysis in rat heart and brain. Science 1988, 242:268-270.
113. Boulanger C, Lüscher TF Release of endothelin from the porcine aorta. Inhibition of endothelium-derived nitric oxide. J Clin Invest 1990, 85:587-590.
114. Boulanger CM, Tanner FC, Bea ML, et al. Oxidized low density lipoproteins induce mRNA expression and release of endothelin from human and porcine endothelium. Circ Res 1992, 70:1191-1197.
115. Yoshizumi M, Kurihara H, Sugiyama T, et al. Hemodynamic shear stress stimulates endothelin production by cultured endothelial cells. Biochem Biophys Res Commun 1989, 161:859-864.
116. Kourembanas S, Marsden PA, McQuillan LP, et al. Hypoxia induces endothelin gene expression and secretion in cultured human endothelium. J Clin Invest 1991, 88:1054-1057.
117. Shirakami G, Nakao K, Saito Y, et al. Acute pulmonary alveolar hypoxia increases lung and plasma endothelin-1 levels in conscious rats. Life Sci 1991, 48:969-976.
118. Hieda HS, Gomez-Sanchez CE Hypoxia increases endothelin release in bovine endothelial cells in culture, but epinephrine, norepinephrine, serotonin, histamine and angiotensin II do not. Life Sci 1990, 47:247-251.
119. Kohno M, Murakawa K, Yokokawa K, et al. Production of endothelin by cultured porcine endothelial cells: Modulation by adrenaline. J Hypertens Suppl 1989, 7:S130-S131.
120. Ohta K, Hirata Y, Imai T, et al. Cytokine-induced release of endothelin-1 from porcine renal epithelial cell line. Biochem Biophys Res Commun 1990, 169:578-584.
121. Kanse SM, Takahashi K, Lam HC, et al. Cytokine stimulated endothelin release from endothelial cells. Life Sci 1991, 48:1379-1384.
122. Miyamori I, Takeda Y, Yoneda T, et al. Interleukin-2 enhances the release of endothelin-1 from the rat mesenteric artery. Life Sci 1991, 49:1295-1300.
123. Woods M, Bishop-Bailey D, Pepper JR, et al. Cytokine and lipopolysaccharide stimulation of endothelin-1 release from human internal mammary artery and saphenous vein smooth-muscle cells. J Cardiovasc Pharmacol 1998, 31:S348-S350.
124. Dohi Y, Hahn AW, Boulanger CM, et al. Endothelin stimulated by angiotensin II augments contractility of spontaneously hypertensive rat resistance arteries. Hypertension 1992, 19:131-137.
125. Barton M, Shaw S, d'Uscio LV, et al. Angiotensin II increases vascular and renal endothelin-1 and functional endothelin converting enzyme activity in vivo: Role of ETA receptors for endothelin regulation. Biochem Biophys Res Commun 1997, 238:861-865.
126. Abassi ZA, Tate JE, Golomb E, et al. Role of neutral endopepti-dase in the metabolism of endothelin. Hypertension 1992, 20:89-95.
127. Abassi ZA, Golomb E, Bridenbaugh R, et al. Metabolism of endothelin-1 and big endothelin-1 by recombinant neutral endopeptidase EC.3.4.24.11. Br J Pharmacol 1993, 109:1024-1028.
128. Lüscher TF Imbalance of endothelium-derived relaxing and contracting factors: A new concept in hypertension?. Am J Hypertens 1990, 317:317-330.
129. Vierhapper H, Wagner O, Nowotny P, et al. Effect of endothelin-1 in man. Circulation 1990, 81:1415-1418.
130. Kiely DG, Cargill RI, Struthers AD, Lipworth BJ Cardiopulmonary effects of endothelin-1 in man. Cardiovasc Res 1997, 33:378-386.
131. Ito H, Hirata Y, Hiroe M, et al. ET-1 induces hypertrophy with enhanced expression of muscle specific genes in cultured neonatal rat cardiomyocytes. Circ Res 1991, 69:209-215.
132. Barton M, d'Uscio LV, Shaw S, et al. ET(A) receptor blockade prevents increased tissue endothelin-1, vascular hypertrophy, and endothelial dysfunction in salt-sensitive hypertension. Hypertension 1998, 31:499-504.
133. Yang Z, Krasnici N, Lüscher TF Endothelin-1 potentiates smooth muscle cell growth to PDGF: Role of ETA and ETB receptor blockade. Circulation 1999, 100:5-8.
134. Kannel WB, Gordon T, Offutt D Left ventricular hypertrophy by electrocardiogram. Prevalence, incidence, and mortality in the Framingham study. Ann Intern Med 1969, 71:89-105.
135. Bots ML, Hoes AW, Koudstaal PJ, et al. Common carotid intima-media thickness and risk of stroke and myocardial infarction: The Rotterdam Study. Circulation 1997, 96:1432-1437.
136. O'Leary DH, Polak JF, Kronmal RA, et al. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N Engl J Med 1999, 340:14-22.
137. Ghiadoni L, Taddei S, Virdis A, et al. Endothelial function and common carotid artery wall thickening in patients with essential hypertension. Hypertension 1998, 32:25-32.
138. Perticone F, Maio R, Ceravolo R, et al. Relationship between left ventricular mass and endothelium-dependent vasodilation in never-treated hypertensive patients. Circulation 1999, 99:1991-1996.
139. Wagner OF, Christ G, Wojta J, et al. Polar secretion of endothelin-1 by cultured endothelial cells. J Biol Chem 1992, 267:16066-16068.
140. Sorensen SS Radio-immunoassay of endothelin in human plasma. Scand J Clin Lab Invest 1991, 51:615-623.
141. Haynes WG, Webb DJ Contribution of endogenous generation of endothelin-1 to basal vascular tone. Lancet 1994, 344:852-854.
142. Haynes WG, Ferro CJ, O'Kane KP, et al. Systemic endothelin receptor blockade decreases peripheral vascular resistance and blood pressure in humans. Circulation 1996, 93:1860-1870.
143. Yang Z, Bauer E, von Segesser L, et al. Different mobilization of calcium in endothelin-1-induced contractions in human arteries and veins: Effects of calcium antagonists. J Cardiovasc Pharmacol 1990, 16:654-660.
144. Yang ZH, Richard V, von Segesser L, et al. Threshold concentrations of endothelin-1 potentiate contractions to norepinephrine and serotonin in human arteries. A new mechanism of vasospasm?. Circulation 1990, 82:188-195.
145. Lysko PG, Feuerstein G, Pullen M, et al. Identification of endothelin receptors in cultured cerebellar neurons. Neuropeptides 1991, 18:83-86.
146. Nambi P, Pullen M, Feuerstein G Identification of endothelin receptors in various regions of rat brain. Neuropeptides 1990, 16:195-199.
147. Knuepfer MM, Han SP, Trapani AJ, et al. Regional hemodynamic and baroreflex effects of endothelin in rats. Am J Physiol 1989, 257:H918-H926.
148. Gardiner SM, Compton AM, Kemp PA, et al. Regional and cardiac haemodynamic responses to glyceryl trinitrate, acetylcholine, bradykinin and endothelin-1 in conscious rats: Effects of NG-nitro-L-arginine methyl ester. Br J Pharmacol 1990, 101:632-639.
149. Nakamoto H, Suzuki H, Murakami M, et al. Different effects of low and high doses of endothelin on haemodynamics and hormones in the normotensive conscious dog. J Hypertens 1991, 9:337-344.
150. Donckier JE, Hanet C, Berbinschi A, et al. Cardiovascular and endocrine effects of endothelin-1 at pathophysiological and pharmacological plasma concentrations in conscious dogs. Circulation 1991, 84:2476-2484.
151. van den Buuse M, Itoh S Central effects of endothelin on baroreflex of spontaneously hypertensive rats. J Hypertens 1993, 11:379-387.
152. Kannan H, Tanaka H, Ueta Y, et al. Effects of centrally administered endothelin-3 on renal sympathetic nerve activity and renal blood flow in conscious rats. J Auton Nerv Syst 1994, 49:105-113.
153. Chapleau MW, Hajduczok G, Abboud FM Suppression of baroreceptor discharge by endothelin at high carotid sinus pressure. Am J Physiol 1992, 263:R103-R108.
154. Mosqueda-Garcia R, Appalsamy M, Fernandez-Violante R, et al. Modulatory effects of endothelin on baroreflex activation in the nucleus of the solitary tract. Eur J Pharmacol 1998, 351:203-207.
155. Sorensen SS, Madsen JK, Pedersen EB Systemic and renal effect of intravenous infusion of endothelin-1 in healthy human volunteers. Am J Physiol 1994, 266:F411-F418.
156. Miyauchi T, Ishikawa T, Tomobe Y, et al. Characteristics of pressor response to endothelin in spontaneously hypertensive and Wistar-Kyoto rats. Hypertension 1989, 14:427-434.
157. Lariviere R, Day R, Schiffrin EL Increased expression of endothelin-1 gene in blood vessels of deoxycorticosterone acetate-salt hypertensive rats. Hypertension 1993, 21:916-920.
158. Lariviere R, Thibault G, Schiffrin EL Increased endothelin-1 content in blood vessels of deoxycorticosterone acetate-salt hypertensive but not in spontaneously hypertensive rats. Hypertension 1993, 21:294-300.
159. Li JS, Lariviere R, Schiffrin EL Effect of a nonselective endothelin antagonist on vascular remodeling in deoxycorticosterone acetate-salt hypertensive rats. Evidence for a role of endothelin in vascular hypertrophy. Hypertension 1994, 24:183-188.
160. Schiffrin EL, Lariviere R, Li JS, et al. Deoxycorticosterone acetate plus salt induces overexpression of vascular endothelin-1 and severe vascular hypertrophy in spontaneously hypertensive rats. Hypertension 1995, 25:769-773.
161. Doucet J, Gonzalez W, Michel JB Endothelin antagonists in salt-dependent hypertension associated with renal insufficiency. J Cardiovasc Pharmacol 1996, 27:643-651.
162. Lariviere R, Sventek P, Schiffrin EL Expression of endothelin-1 gene in blood vessels of adult spontaneously hypertensive rats. Life Sci 1995, 56:1889-1896.
163. Hocher B, Rohmeiss P, Zart R, et al. Significance of endothelin receptor subtypes in the kidneys of spontaneously hypertensive rats: Renal and hemodynamic effects of endothelin receptor antagonists. J Cardiovasc Pharmacol 1995, 26:S470-S472.
164. Hocher B, Rohmeiss P, Zart R, et al. Function and expression of endothelin receptor subtypes in the kidneys of spontaneously hypertensive rats. Cardiovasc Res 1996, 31:499-510.
165. Hocher B, George I, Rebstock J, et al. Endothelin system-dependent cardiac remodeling in renovascular hypertension. Hypertension 1999, 33:816-822.
166. Saito Y, Nakao K, Mukoyama M, et al. Increased plasma endothelin level in patients with essential hypertension [letter]. N Engl J Med 1990, 322:205.
167. Miyauchi T, Yanagisawa M, Iida K, et al. Age- and sex-related variation of plasma endothelin-1 concentration in normal and hypertensive subjects. Am Heart J 1992, 123:1092-1093.
168. Haynes WG, Ferro CJ, Webb DJ Bosentan in essential hypertension [letter; comment]. N Engl J Med 1998, 339:346. discussion 347.
169. Rossi GP, Colonna S, Pavan E, et al. Endothelin-1 and its mRNA in the wall layers of human arteries ex vivo. Circulation 1999, 99:1147-1155.
170. Stevens PA, Brown MJ Genetic variability of the ET-1 and the ETA receptor genes in essential hypertension. J Cardiovasc Pharmacol 1995, 26:S9-S12.
171. Tiret L, Poirier O, Hallet V, et al. The Lys198Asn polymorphism in the endothelin-1 gene is associated with blood pressure in overweight people. Hypertension 1999, 33:1169-1174.
172. Nicaud V, Poirier O, Behague I, et al. Polymorphisms of the endothelin-A and -B receptor genes in relation to blood pressure and myocardial infarction: The Etude Cas-Temoins sur l'Infarctus du Myocarde (ECTIM) Study. Am J Hypertens 1999, 12:304-310.
173. Sharma P, Hingorani A, Jia H, et al. Quantitative association between a newly identified molecular variant in the endothe-lin-2 gene and human essential hypertension. J Hypertens 1999, 17:1281-1287.
174. Lüscher TF, Vanhoutte PM, Raij L Antihypertensive treatment normalizes decreased endothelium-dependent relaxations in rats with salt-induced hypertension. Hypertension 1987, 9:193-197.
175. Tschudi MR, Criscione L, Novosel D, et al. Antihypertensive therapy augments endothelium-dependent relaxations in coronary arteries of spontaneously hypertensive rats. Circulation 1994, 89:2212-2218.
176. d'Uscio LV, Shaw S, Barton M, et al. Losartan but not verapamil inhibits angiotensin II-induced tissue endothelin-1 increase: Role of blood pressure and endothelial function. Hypertension 1998, 31:1305-1310.
177. Maeso R, Rodrigo E, Munoz-Garcia R, et al. Chronic treatment with losartan ameliorates vascular dysfunction induced by aging in spontaneously hypertensive rats. J Hypertens 1998, 16:665-672.
178. Rodrigo E, Maeso R, Munoz-Garcia R, et al. Endothelial dysfunction in spontaneously hypertensive rats: Consequences of chronic treatment with losartan or captopril. J Hypertens 1997, 15:613-618.
179. Boulanger CM, Desta B, Clozel JP, Vanhoutte PM Chronic treatment with the CA2+ channel inhibitor RO 40-5967 potentiates endothelium-dependent relaxations in the aorta of the hypertensive salt sensitive Dahl rat. Blood Press 1994, 3:193-196.
180. Dohi Y, Criscione L, Pfeiffer K, et al. Angiotensin blockade or calcium antagonists improve endothelial dysfunction in hypertension: Studies in perfused mesenteric resistance arteries. J Cardiovasc Pharmacol 1994, 24:372-379.
181. Panza JA, Garcia CE, Kilcoyne CM, et al. Impaired endothelium-dependent vasodilation in patients with essential hypertension. Evidence that nitric oxide abnormality is not localized to a single signal transduction pathway. Circulation 1995, 91:1732-1738.
182. Creager MA, Roddy M-A, Coleman SM, et al. The effect of ACE inhibition on endothelium-dependent vasodilation in hypertension. J Vasc Res 1992, 29:97.
183. Taddei S, Virdis A, Ghiadoni L, et al. Effects of angiotensin converting enzyme inhibition on endothelium-dependent vasodilatation in essential hypertensive patients. J Hypertens 1998, 16:447-456.
184. Lyons D, Webster J, Benjamin N The effect of antihypertensive therapy on responsiveness to local intra-arterial NG-monomethyl-L-arginine in patients with essential hypertension. J Hypertens 1994, 12:1047-1052.
185. Millgard J, Hagg A, Sarabi M, et al. Captopril, but not nifedipine, improves endothelium-dependent vasodilation in hypertensive patients. J Hum Hypertens 1998, 12:511-516.
186. Schiffrin EL, Deng LY, Larochelle P Progressive improvement in the structure of resistance arteries of hypertensive patients after 2 years of treatment with an angiotensin I-converting enzyme inhibitor. Comparison with effects of a beta-blocker. Am J Hypertens 1995, 8:229-236.
187. Ghiadoni L, Virdis A, Magagna A, et al. Effect of the angiotensin II type 1 receptor blocker candesartan on endothelial function in patients with essential hypertension. Hypertension 2000, 35:501-506.
188. Dawes M, Brett SE, Chowienczyk PJ, et al. The vasodilator action of nebivolol in forearm vasculature of subjects with essential hypertension. Br J Clin Pharmacol 1999, 48:460-463.
189. Sudano I, Taddei S, Virdis A, et al. Nifedipine enhances endothelium-dependent relaxation and inhibits contractions to endothelin-1 and phenylephrine in hypertension. J Hypertens 1998, 16:1115. (abstract).
190. Schiffrin EL, Deng LY Structure and function of resistance arteries of hypertensive patients treated with a beta-blocker or a calcium channel antagonist. J Hypertens 1996, 14:1247-1255.
191. Taddei S, Virdis A, Ghiadoni L, et al. Lacidipine restores endothelium-dependent vasodilation in essential hypertensive patients. Hypertension 1997, 30:1606-1612.
192. Perticone F, Ceravolo R, Maio R, et al. Calcium antagonist isradipine improves abnormal endothelium-dependent vasodilation in never treated hypertensive patients. Cardiovasc Res 1999, 41:299-306.
193. Cockcroft JR, Chowienczyk PJ, Benjamin N, et al. Preserved endothelium-dependent vasodilatation in patients with essential hypertension. N Engl J Med 1994, 330:1036-1040.
194. Perticone F, Ceravolo R, Maio R, et al. Angiotensin-converting enzyme gene polymorphism is associated with endothelium-dependent vasodilation in never treated hypertensive patients. Hypertension 1998, 31:900-905.
195. Taddei S, Virdis A, Ghiadoni L, et al. Vitamin C improves endothelium-dependent vasodilation by restoring nitric oxide activity in essential hypertension. Circulation 1998, 97:2222-2229.
196. Nakazono K, Watanabe N, Matsuno K, et al. Does superoxide underlie the pathogenesis of hypertension?. Proc Natl Acad Sci USA 1991, 88:10045-10048.
197. Duffy SJ, Gokce N, Holbrook M, et al. Treatment of hypertension with ascorbic acid. Lancet 1999, 354.
198. Cockcroft JR, Chowienczyk PJ, Brett SE, et al. Nebivolol vasodilates human forearm vasculature: Evidence for an L-arginine/NO-dependent mechanism. J Pharmacol Exp Ther 1995, 274:1067-1071.
199. Bowman AJ, Chen CP, Ford GA Nitric oxide mediated ven-odilator effects of nebivolol. Br J Clin Pharmacol 1994, 38:199-204.
200. Van Nueten L, De Cree J Nebivolol: Comparison of the effects of dl-nebivolol, d-nebivolol, l-nebivolol, atenolol, and placebo on exercise-induced increases in heart rate and systolic blood pressure. Cardiovasc Drugs Ther 1998, 12:339-344.
201. Wallin BG, Sundlof G, Stromgren E, et al. Sympathetic outflow to muscles during treatment of hypertension with metoprolol. Hypertension 1984, 6:557-662.
202. Spieker LE, Corti R, Binggeli C, et al. Baroreceptor dysfunction induced by nitric oxide synthase inhibition in humans. J Am Coll Cardiol 2000, 36:213-218.
203. Spieker LE, Noll G, Ruschitzka FT, et al. Working under pressure: The vascular endothelium in arterial hypertension. J Hum Hypertens 2000, 14:617-630.
204. Lüscher TF, Noll G Endothelium-derived vasoactive substances. Heart Disease. 5th ed 1997, 1165. WB Saunders, Philadelphia. E. Braunwald (Ed.).